Search results
Results from the WOW.Com Content Network
Gliclazide, sold under the brand name Diamicron among others, is a sulfonylurea type of anti-diabetic medication, used to treat type 2 diabetes. [7] It is used when dietary changes, exercise, and weight loss are not enough. [4] It is taken by mouth. [7] Side effect may include low blood sugar, vomiting, abdominal pain, rash, and liver problems.
Insulin glargine/lixisenatide is approved as a prescription for adults with type 2 diabetes mellitus poorly controlled by lixisenatide or basal insulin alone. [6] According to the American Diabetes Association, combination treatment of a GLP-1 receptor agonist with basal insulin should occur after HbA1C levels remain above target (7% for most type 2 people with diabetes) following use of basal ...
In some cases, people with no kidney disease have had acute kidney injury and in some people with existing kidney disease the condition has gotten worse. [3] Because lixisenatide is a peptide people can and do develop an immune response to it that will eventually make the drug ineffective; people who have developed antibodies to lixisenatide ...
The American Association of Clinical Endocrinologists (AACE), which provides clinical practice guidelines for management of diabetes, retains thiazolidinediones as recommended first, second, or third line agents for type 2 diabetes mellitus, as of their 2019 executive summary, over sulfonylureas and α-glucosidase inhibitors.
The United States Food and Drug Administration (FDA) has defined bioequivalence as, "the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose ...
Tirzepatide was approved for treatment of diabetes in the United States in May 2022, [9] [13] in the European Union in September 2022, [11] in Canada in November 2022, [19] and in Australia in December 2022. [2] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Insulin degludec is an ultra-long acting insulin that, unlike insulin glargine, is active at a physiologic pH.The addition of hexadecanedioic acid via an amide linkage to lysine at the B29 position allows for the formation of multi-hexamers in subcutaneous tissues. [16]
The normal, nondiabetic range for fasting blood glucose is between 70 and 110 mg/dL (5 – 7 mmol/L), depending on the person (there is some variations between individuals), whether the blood is from a vein or a capillary, and depending on how the measurement is made (e.g., on whole blood or just the plasma).